Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury

Tomoyuki Yoshihara, Masayoshi Ohta, Yutaka Itokazu, Naoya Matsumoto, Mari Dezawa, Yoshihisa Suzuki, Akihiko Taguchi, Yumi Watanabe, Yasushi Adachi, Susumu Ikehara, Hisashi Sugimoto, Chizuka Ide

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Neural cell transplantation, a new therapeutic strategy for replacing injured neural components and obtaining functional recovery, has shown beneficial effects in animal models. Use of this strategy in human patients, however, requires that a number of serious issues be addressed, including ethics, immunorejection, and the therapeutic time window within which the procedure will be effective. Bone marrow-derived mononuclear cells (BM-MNC) are attractive for transplantation because they can be used as an autograft, can be easily collected within a short time period, and do not have to be cultured. In a rat model of spinal cord injury (SCI), we transplanted BM-MNC at 1 h after SCI at Th 8-9 by injecting them into the cerebrospinal fluid (CSF), and investigated the effect of this on neurologic function. In the acute stage of injury, we found a neuroprotective antiapoptotic effect, with an elevated concentration of hepatocyte growth factor in CSF. At 1 week after transplantation, the Basso-Beattie-Bresnahan locomotor score had increased significantly over its baseline value. In the chronic stage of injury, we observed suppressed cavity formation and functional improvement. We conclude that transplantation of BM-MNC after SCI has a remarkable neuroprotective effect in the acute stage of injury, suppressing cavity formation, and contributing to functional recovery. Our results suggest that transplantation of BM-MNC via the CSF is a potentially effective means of enhancing functional recovery after SCI in humans.

Original languageEnglish (US)
Pages (from-to)1026-1036
Number of pages11
JournalJournal of Neurotrauma
Volume24
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Neuroprotective Agents
Spinal Cord Injuries
Bone Marrow
Cerebrospinal Fluid
Cell Transplantation
Bone Marrow Transplantation
Wounds and Injuries
Hepatocyte Growth Factor
Autografts
Ethics
Nervous System
Animal Models
Transplantation
Therapeutics

Keywords

  • Bone marrow-derived mononuclear cell
  • Cell transplantation
  • Cerebrospinal fluid
  • Neuroprotection
  • Spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. / Yoshihara, Tomoyuki; Ohta, Masayoshi; Itokazu, Yutaka; Matsumoto, Naoya; Dezawa, Mari; Suzuki, Yoshihisa; Taguchi, Akihiko; Watanabe, Yumi; Adachi, Yasushi; Ikehara, Susumu; Sugimoto, Hisashi; Ide, Chizuka.

In: Journal of Neurotrauma, Vol. 24, No. 6, 01.06.2007, p. 1026-1036.

Research output: Contribution to journalArticle

Yoshihara, T, Ohta, M, Itokazu, Y, Matsumoto, N, Dezawa, M, Suzuki, Y, Taguchi, A, Watanabe, Y, Adachi, Y, Ikehara, S, Sugimoto, H & Ide, C 2007, 'Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury', Journal of Neurotrauma, vol. 24, no. 6, pp. 1026-1036. https://doi.org/10.1089/neu.2007.132R
Yoshihara, Tomoyuki ; Ohta, Masayoshi ; Itokazu, Yutaka ; Matsumoto, Naoya ; Dezawa, Mari ; Suzuki, Yoshihisa ; Taguchi, Akihiko ; Watanabe, Yumi ; Adachi, Yasushi ; Ikehara, Susumu ; Sugimoto, Hisashi ; Ide, Chizuka. / Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. In: Journal of Neurotrauma. 2007 ; Vol. 24, No. 6. pp. 1026-1036.
@article{38684385f1f3441ba2b37eede0e22186,
title = "Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury",
abstract = "Neural cell transplantation, a new therapeutic strategy for replacing injured neural components and obtaining functional recovery, has shown beneficial effects in animal models. Use of this strategy in human patients, however, requires that a number of serious issues be addressed, including ethics, immunorejection, and the therapeutic time window within which the procedure will be effective. Bone marrow-derived mononuclear cells (BM-MNC) are attractive for transplantation because they can be used as an autograft, can be easily collected within a short time period, and do not have to be cultured. In a rat model of spinal cord injury (SCI), we transplanted BM-MNC at 1 h after SCI at Th 8-9 by injecting them into the cerebrospinal fluid (CSF), and investigated the effect of this on neurologic function. In the acute stage of injury, we found a neuroprotective antiapoptotic effect, with an elevated concentration of hepatocyte growth factor in CSF. At 1 week after transplantation, the Basso-Beattie-Bresnahan locomotor score had increased significantly over its baseline value. In the chronic stage of injury, we observed suppressed cavity formation and functional improvement. We conclude that transplantation of BM-MNC after SCI has a remarkable neuroprotective effect in the acute stage of injury, suppressing cavity formation, and contributing to functional recovery. Our results suggest that transplantation of BM-MNC via the CSF is a potentially effective means of enhancing functional recovery after SCI in humans.",
keywords = "Bone marrow-derived mononuclear cell, Cell transplantation, Cerebrospinal fluid, Neuroprotection, Spinal cord injury",
author = "Tomoyuki Yoshihara and Masayoshi Ohta and Yutaka Itokazu and Naoya Matsumoto and Mari Dezawa and Yoshihisa Suzuki and Akihiko Taguchi and Yumi Watanabe and Yasushi Adachi and Susumu Ikehara and Hisashi Sugimoto and Chizuka Ide",
year = "2007",
month = "6",
day = "1",
doi = "10.1089/neu.2007.132R",
language = "English (US)",
volume = "24",
pages = "1026--1036",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Neuroprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury

AU - Yoshihara, Tomoyuki

AU - Ohta, Masayoshi

AU - Itokazu, Yutaka

AU - Matsumoto, Naoya

AU - Dezawa, Mari

AU - Suzuki, Yoshihisa

AU - Taguchi, Akihiko

AU - Watanabe, Yumi

AU - Adachi, Yasushi

AU - Ikehara, Susumu

AU - Sugimoto, Hisashi

AU - Ide, Chizuka

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Neural cell transplantation, a new therapeutic strategy for replacing injured neural components and obtaining functional recovery, has shown beneficial effects in animal models. Use of this strategy in human patients, however, requires that a number of serious issues be addressed, including ethics, immunorejection, and the therapeutic time window within which the procedure will be effective. Bone marrow-derived mononuclear cells (BM-MNC) are attractive for transplantation because they can be used as an autograft, can be easily collected within a short time period, and do not have to be cultured. In a rat model of spinal cord injury (SCI), we transplanted BM-MNC at 1 h after SCI at Th 8-9 by injecting them into the cerebrospinal fluid (CSF), and investigated the effect of this on neurologic function. In the acute stage of injury, we found a neuroprotective antiapoptotic effect, with an elevated concentration of hepatocyte growth factor in CSF. At 1 week after transplantation, the Basso-Beattie-Bresnahan locomotor score had increased significantly over its baseline value. In the chronic stage of injury, we observed suppressed cavity formation and functional improvement. We conclude that transplantation of BM-MNC after SCI has a remarkable neuroprotective effect in the acute stage of injury, suppressing cavity formation, and contributing to functional recovery. Our results suggest that transplantation of BM-MNC via the CSF is a potentially effective means of enhancing functional recovery after SCI in humans.

AB - Neural cell transplantation, a new therapeutic strategy for replacing injured neural components and obtaining functional recovery, has shown beneficial effects in animal models. Use of this strategy in human patients, however, requires that a number of serious issues be addressed, including ethics, immunorejection, and the therapeutic time window within which the procedure will be effective. Bone marrow-derived mononuclear cells (BM-MNC) are attractive for transplantation because they can be used as an autograft, can be easily collected within a short time period, and do not have to be cultured. In a rat model of spinal cord injury (SCI), we transplanted BM-MNC at 1 h after SCI at Th 8-9 by injecting them into the cerebrospinal fluid (CSF), and investigated the effect of this on neurologic function. In the acute stage of injury, we found a neuroprotective antiapoptotic effect, with an elevated concentration of hepatocyte growth factor in CSF. At 1 week after transplantation, the Basso-Beattie-Bresnahan locomotor score had increased significantly over its baseline value. In the chronic stage of injury, we observed suppressed cavity formation and functional improvement. We conclude that transplantation of BM-MNC after SCI has a remarkable neuroprotective effect in the acute stage of injury, suppressing cavity formation, and contributing to functional recovery. Our results suggest that transplantation of BM-MNC via the CSF is a potentially effective means of enhancing functional recovery after SCI in humans.

KW - Bone marrow-derived mononuclear cell

KW - Cell transplantation

KW - Cerebrospinal fluid

KW - Neuroprotection

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=34347326019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347326019&partnerID=8YFLogxK

U2 - 10.1089/neu.2007.132R

DO - 10.1089/neu.2007.132R

M3 - Article

C2 - 17600518

AN - SCOPUS:34347326019

VL - 24

SP - 1026

EP - 1036

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 6

ER -